Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

Authors
Category Primary study
JournalBlood
Year 2020
This article has no abstract
Epistemonikos ID: 3b7e6a12b951408d3334081f1f5f0e187e16c734
First added on: Feb 12, 2025